Chemoprevention of breast cancer: recommendations and rationale.
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000517:prevention & control*; D018890:Chemoprevention; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D011322:Primary Prevention; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride